nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2020-2-104-108nnp-1313Research ArticleREVIEWSОБЗОРЫThe history of mianserin and mirtazapine: study of their neurochemical activity and determination of their position in the classification of antidepressantsИстория миансерина и миртазапина: изучение нейрохимической активности и определение положения в классификации антидепрессантовДаниловД. С.DanilovD. S.clinica2001@inbox.ruТюльпинЮ. Г.TyulpinYu. G.МорозоваВ. Д.MorozovaV. D.Клиника психиатрии им. С.С. Корсакова Университетской клинической больницы №3 и кафедра психиатрии и наркологии Института клинической медицины ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияS.S. Korsakov Clinic of Psychiatry, University Clinical Hospital Three and Department of Psychiatry and Narcology, Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaRussian Federation202019042020122104108Copyright © Danilov D.S., Tyulpin Y.G., Morozova V.D., 20202020Данилов Д.С., Тюльпин Ю.Г., Морозова В.Д.Danilov D.S., Tyulpin Y.G., Morozova V.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/1313миансеринмиртазапинα2-адренорецепторысеротониновые 5-НТ2-рецепторынорадреналинсеротонинблокаторы α2-адренорецепторовнорадреналинергические и специфические серотонинергические антидепрессантыстимуляторы
высвобождения норадреналина и серотонина – блокаторы α2-адренорецепторов и серотониновых 5-НТ2-рецепторовистория антидепрессантовmianserinmirtazapineα2-adrenergic receptorsserotonin 5-HT2 receptorsnorepinephrineserotoninα2-adrenergic receptor blockersnoradrenalinergic and specific serotonergic antidepressantsnorepinephrine and serotonin release stimulators – α2-adrenergic and serotonin 5-HT2 receptor blockershistory of antidepressantsReferencesMarshall RJ. The pharmacology of mianserin – an update. Br J Clin Pharmacol. 1983;15 Suppl 2:263S-268S.Marshall RJ. The pharmacology of mianserin – an update. Br J Clin Pharmacol. 1983;15 Suppl 2:263S-268S.Балдессарини Р. Медикаментозное лечение депрессии и тревожных расстройств. В кн.: Клиническая фармакология по Гудману и Гилману. Москва: Практика; 2006. С. 350-82.Baldessarini R. Medikamentoznoe lechenie depressii i trevozhnykh rasstroistv. V kn.: Klinicheskaya farmakologiya po Gudmanu i Gilmanu. Moskva: Praktika; 2006. S. 350-82. In: Klinicheskaya farmakologiya po Gudmanu i Gilmanu [Clinical pharmacology by Goodman and Gilman]. Moscow: Praktika; 2006. P. 350-82.Maj J. Serotoninergic mechanisms of antidepressant drugs. Gesundheitswesen. 2015 Nov; 77(11):880. doi: 10.1055/s-0035-1563376. Epub 2015 Nov 25.Maj J. Serotoninergic mechanisms of antidepressant drugs. Gesundheitswesen. 2015 Nov; 77(11):880. doi: 10.1055/s-0035-1563376. Epub 2015 Nov 25.Pettibone DJ, Pflueger AB. Effects of methiothepin and lysergic acid diethylamide on serotonin release in vitro and serotonin synthesis in vivo: possible relation to serotonin autoreceptor function. J Neurochem. 1984 Jul; 43(1):83-90.Pettibone DJ, Pflueger AB. Effects of methiothepin and lysergic acid diethylamide on serotonin release in vitro and serotonin synthesis in vivo: possible relation to serotonin autoreceptor function. J Neurochem. 1984 Jul; 43(1):83-90.Raiteri M, Maura G, Versace P. Functional evidence for two stereochemically different alpha-2 adrenoceptors regulating central norepinephrine and serotonin release. J Pharmacol Exp Ther. 1983 Mar;224(3):679-84.Raiteri M, Maura G, Versace P. Functional evidence for two stereochemically different alpha-2 adrenoceptors regulating central norepinephrine and serotonin release. J Pharmacol Exp Ther. 1983 Mar;224(3):679-84.de Boer TH, Nefkens F, van Helvoirt A, et al. Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan. J Pharmacol Exp Ther. 1996 May; 277(2):852-60.de Boer TH, Nefkens F, van Helvoirt A, et al. Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan. J Pharmacol Exp Ther. 1996 May; 277(2):852-60.Nagayasu K, Kitaichi M, Nishitani N, et al. Chronic effects of antidepressants on serotonin release in rat raphe slice cultures: high potency of milnacipran in the augmentation of serotonin release. Int J Neuropsychopharmacol. 2013 Nov; 16(10):2295-306. doi: 10.1017/S1461145713000 771. Epub 2013 Aug 7.Nagayasu K, Kitaichi M, Nishitani N, et al. Chronic effects of antidepressants on serotonin release in rat raphe slice cultures: high potency of milnacipran in the augmentation of serotonin release. Int J Neuropsychopharmacol. 2013 Nov; 16(10):2295-306. doi: 10.1017/S1461145713000 771. Epub 2013 Aug 7.de Boer TH, Maura G, Raiteri M, et al. Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408.de Boer TH, Maura G, Raiteri M, et al. Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408.Westenberg HG. Pharmacology of antidepressants: selectivity or multiplicity? J Clin Psychiatry. 1999;60 Suppl 17:4-8.Westenberg HG. Pharmacology of antidepressants: selectivity or multiplicity? J Clin Psychiatry. 1999;60 Suppl 17:4-8.de Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol. 1995 Dec;10 Suppl 4:19-23.de Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol. 1995 Dec;10 Suppl 4:19-23.de Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry. 1996;57 Suppl 4:19-25.de Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry. 1996;57 Suppl 4:19-25.Millan MJ, Gobert A, Rivet JM, et al. Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci. 2000 Mar;12(3):1079-95.Millan MJ, Gobert A, Rivet JM, et al. Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci. 2000 Mar;12(3):1079-95.Bengtsson HJ, Kele J, Johansson J, et al. Interaction of the antidepressant mirtazapine with alpha2-adrenoceptors modulating the release of 5-HT in different rat brain regions in vivo. Naunyn Schmiedebergs Arch Pharmacol. 2000 Nov;362(4-5):406-12.Bengtsson HJ, Kele J, Johansson J, et al. Interaction of the antidepressant mirtazapine with alpha2-adrenoceptors modulating the release of 5-HT in different rat brain regions in vivo. Naunyn Schmiedebergs Arch Pharmacol. 2000 Nov;362(4-5):406-12.Gillman PK. A systematic review of the serotonergic effects of mirtazapine: implications for its dual action status. Hum Psychopharmacol. 2006 Mar;21(2):117-25.Gillman PK. A systematic review of the serotonergic effects of mirtazapine: implications for its dual action status. Hum Psychopharmacol. 2006 Mar;21(2):117-25.Gillman PK. Mirtazapine, a paradigm of mediocre science in a deficient regulatory environment. https://psychotropical.com/mirtazapine-a-paradigm-of-mediocre-science/Gillman PK. Mirtazapine, a paradigm of mediocre science in a deficient regulatory environment. https://psychotropical.com/mirtazapine-a-paradigm-of-mediocre-science/Pinder RM. Designing a new generation of antidepressant drugs. Acta Psychiatr Scand Suppl. 1997;391:7-13.Pinder RM. Designing a new generation of antidepressant drugs. Acta Psychiatr Scand Suppl. 1997;391:7-13.Feighner JP. Mechanism of action of antidepressant medications. J Clin Psychiatry. 1999;60 Suppl 4:4-11.Feighner JP. Mechanism of action of antidepressant medications. J Clin Psychiatry. 1999;60 Suppl 4:4-11.Сюняков ТС. Аффективные расстройства – междисциплинарная проблема. Новые возможности в диагностике, лечении и профилактике (обзор материалов конференции). Психиатрия и психофармакотерапия. 2012;14(1):69-72.Syunyakov TS. Affective disorders are an interdisciplinary problem. New opportunities in diagnostics, treatment and prevention (review of conference materials). Psikhiatriya i psikhofarmakoterapiya. 2012;14(1):69-72. (In Russ.).Мосолов СН. Клиническое применение современных антидепрессантов. Санкт-Петербург: МИА; 1995. 564 с.Clinical use of modern antidepressants]. Saint-Petersburg: MIA; 1995. 564 p.Яничак ФД, Дэвис ДМ, Прескорн ШХ и др. Принципы и практика психофармакотерапии. Киев: Ника-Центр; 1999. 728 с.Yanichak FD, Devis DM, Preskorn ShKh, et al. Printsipy i praktika psikhofarmakoterapii [Principles and practice of psychopharmacotherapy]. Kiev: Nika-Tsentr; 1999. 728 p.Montgomery S. Why do we need new and improved antidepressants? Medicographia. 2005;27(3):213-6.Montgomery S. Why do we need new and improved antidepressants? Medicographia. 2005;27(3):213-6.Раевский КС. Антидепрессанты: нейрохимические аспекты механизма действия. Психиатрия и психофармакотерапия. 2001;3(5):162-6.Raevskii KS. Antidepressants: neurochemical aspects of the mechanism of action. Psikhiatriya i psikhofarmakoterapiya. 2001;3(5):162-6. (In Russ.)Андрусенко МП. Антидепрессанты: соотношение особенностей нейрохимического действия и клинических эффектов при лечении депрессий. Психиатрия и психофармакотерапия. 2005;7(5):273-9.Andrusenko MP. Antidepressants: correlation of neurochemical properties and clinical effects in the treatment of depression. Psikhiatriya i psikhofarmakoterapiya. 2005;7(5):273-9. (In Russ.)Мосолов СН. Фармакотерапия психических расстройств. В кн.: Гофман АГ, редактор. Психиатрия: справочник практического врача. 2-е изд. Москва: МЕДпресс-Информ; 2010. С. 371-445.Mosolov SN. Pharmacotherapy of mental disorders. In: Gofman AG, editor. Psikhiatriya: spravochnik prakticheskogo vracha [Psychiatry: a Handbook of a practical physician]. 2nd ed. Moscow: MEDpress-Inform; 2010. P. 371-445.Александровский ЮА, Незнанов НГ, редакторы. Психиатрия: национальное руководство. Москва: ГЭОТАР-Медиа; 2018. 1008 с.Aleksandrovskii YuA, Neznanov NG, editors. Psikhiatriya: natsional'noe rukovodstvo [Psychiatry: national guidelines]. Moscow: GEOTAR-Media; 2018. 1008 p.Козловский ВЛ. Психотропные препараты: от теории к практике. Санкт-Петербург: Спецлит; 2018. 175 с.Kozlovskii VL. Psikhotropnye preparaty: ot teorii k praktike [Psychotropic drugs: from theory to practice]. Saint-Petersburg: Spetslit; 2018. 175 p.Ахапкин РВ, Букреева НД, Вазагаева ТИ и др. Проект клинических рекомендаций «Депрессивный эпизод, Рекуррентной депрессивное расстройство». Российское общество психиатров. 2019. 67 с.Akhapkin RV, Bukreeva ND, Vazagaeva TI, et al. The project of clinical recommendations «Depressive episode, Recurrent depressive disorder». Rossiiskoe obshchestvo psikhiatrov. 2019. 67 p.
The authors declare that there are no conflicts of interest present.